Lupin has informed about submission of a Press Release as regards successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency, the regulatory agency of the United Kingdom (UK) at the Company's three manufacturing units in Pithampur (India). This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company's filings submitted to BSE.